You can expect to learn from the latest evidence-based guidelines, algorithms, consensus statements, and educational resources for diagnosing, managing, and treating these conditions.
10/7/2024
CME: 1 ABIM-MOC: 1
Starts 10/7/2024 | Expires 10/7/2025
Join endocrine experts Mike Lewiecki, MD, and Ranjodh Gill, MD, FACE, FACP, CCD, for an on demand recording of their webinar on recognizing and treating X-linked hypophosphatemia, designed to help clinicians establish a diagnostic path for this lifelong progressive disease.
10/14/2024
CME: 1 ABIM MOC: 1
Starts 10/14/2024 | Expires 10/14/2025
AACE Rare Endocrine Disease Series is pleased to present Are these Changes in my Health Significant? Identifying and Treating Cushing’s Syndrome, a course designed to help clinicians create a path to diagnosis when encountering a patient with Cushing's Syndrome.
10/21/2024
CME: 1 Nursing: 1
AACE Rare Endocrine Disease Series is pleased to present Acromegaly Puzzle: Clinical Clues to Earlier Diagnosis Challenges and Treatment Options, a course designed to help clinicians create a path to diagnosis when encountering a patient with acromegaly.
10/28/2024
CME: 1 ABIM MOC: 1
Starts 10/28/2024 | Expires 10/28/2025
AACE Rare Endocrine Disease Series is pleased to present Fatigue, Abnormal Body Composition and Bone Loss: Is Adult GHD to Be Blamed? This course is designed to help clinicians create a path to diagnosis when encountering a patient with growth hormone deficiency.
This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies.
This guideline provides recommendations on identification, screening, assessment, diagnosis, and treatment of a range of individuals with various causes of adult growth-hormone deficiency (GHD) and patients with childhood-onset GHD transitioning to adult care.
This statement addresses the use of somatostatin-receptor ligands (SRLs) as preoperative therapy for individuals with acromegaly to improve outcomes.
